A new method of producing NS5A antigen of hepatitis C virus

Cover Page


Cite item

Full Text

Abstract

A task of creating a universal platform for engineering affordable recombinant producers of viral proteins conserving immunogenicity has not been solved yet. High toxicity of the viral proteins for the host cells, low yield and abnormal folding of the products often present severe obstacles to obtaining producers of the viral proteins. In this work, we report a new method of engineering and screening of deletion libraries from the viral antigen genes. This method allows selection of artificial derivatives of these genes adapted for expression in microbial producer cells. The method involves PCR amplification of the gene fragments using a system of randomized and adapter primers, which allows the spontaneous formation of duplexes from the random primers in the absence of the template DNA to be prevented. For selecting variants capable of in vivo expression, the obtained PCR products are cloned to a special vector of a direct phenotypical selection pQL30. It contains E. coli β-galactosidase gene with an inserted polylinker producing a frame-shift mutation. Using this screening method, an artificial variant of hepatitis C (HCV) NS5a gene with optimal biotechnological properties was established. 27 clinical specimens of 1670 bp long HCV1b NS5a fragments were used as a source gene. A PCR bank of the deletion derivatives was produced. 40 LacZ-positive clones based on pQL30 vector with a 50-700 bp long insertion were selected. The LacZ activity of the cell lysates and the immunogenicity of the products were tested. As a result, a single clone encoding a soluble protein with Mr = 114 kDa was selected. Its yield reached 0.3% of the total cell protein. It was highly reactive with sera of HCV 1b infected patients but not with sera of the healthy donors.

About the authors

T. V. Kuznetsova

Chumakov institute of Poliomyelitis and Viral Encephalitides; National institute of Public Health Development

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

M. S. Smirnova

Chumakov institute of Poliomyelitis and Viral Encephalitides

Email: noemail@neicon.ru
Russian Federation

O. A. Leonovich

Chumakov institute of Poliomyelitis and Viral Encephalitides

Email: noemail@neicon.ru
Russian Federation

I. V. Gordeichuk

Chumakov institute of Poliomyelitis and Viral Encephalitides

Email: noemail@neicon.ru
Russian Federation

I. K. Biriukova

Chumakov institute of Poliomyelitis and Viral Encephalitides

Email: kudykina_yuliya@mail.ru
Russian Federation

M. V. Zylkova

Chumakov institute of Poliomyelitis and Viral Encephalitides

Email: noemail@neicon.ru
Russian Federation

Ya. Ya. Tyn’O

Chumakov institute of Poliomyelitis and Viral Encephalitides

Email: noemail@neicon.ru
Russian Federation

A. V. Belyakova

Chumakov institute of Poliomyelitis and Viral Encephalitides

Email: noemail@neicon.ru
Russian Federation

A. B. Shevelev

Chumakov institute of Poliomyelitis and Viral Encephalitides

Email: noemail@neicon.ru
Russian Federation

References

  1. Benkovic S.J., Putney S.D., Schimmel P.R. Method for Degrading DNA. Patent USA № 4521509; 1985.
  2. Sugino Y., Morita M., Matuo Y., Uchida K. Method for Producing DNA Nested Deletions by an in Vitro Reaction Using Transposase. Patent USA № 6265159; 2001.
  3. Whitcomb J.M., Rashtchian A., Hughes S.H. A new PCR based method for the generation of nested deletions. Nucleic Acids Res. 1993; 21(17): 4143-6.
  4. Bouzgarrou N., Hassen E., Mahfoudh W., Gabbouj S., Schvoerer E., Ben Yahia A. et al. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy. J. Med. Virol. 2009; 81(12): 2021-8.
  5. MacDonald A., Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 2004; 85(9): 2485-502.
  6. Muñoz de Rueda P., Casado J., Patón R., Quintero D., Palacios A., Gila A. et al. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J. Virol. 2008; 82(13): 6644-53.
  7. Noguchi T., Tamori A., Ogura N., Hori Y., Ikeda S., Nishiguchi S. Investigation of interferon-α response by a single amino acid substitution of nonstructural protein 5A in hepatitis C virus-infected patients. J. Interferon Cytokine Res. 2011; 31(8): 589-99.
  8. Sillanpää M., Melén K., Porkka P., Fagerlund R., Nevalainen K., Lappalainen M. et al. Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection. J.Virol. 2009; 6: 84.
  9. Desombere I., Van Vlierberghe H., Weiland O., Hultgren C., Sällberg M., Quiroga J. et al. Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. J. Med Virol. 2007; 79(6): 701-13.
  10. Swadling L., Capone S., Antrobus R.D., Brown A., Richardson R., Newell E.W. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 2014; 6(261): 261ra153.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Kuznetsova T.V., Smirnova M.S., Leonovich O.A., Gordeichuk I.V., Biriukova I.K., Zylkova M.V., Tyn’O Y.Y., Belyakova A.V., Shevelev A.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies